BMS has welcomed the recently announced listing of immunotherapy combination OPDIVO (nivolumab) in combination with YERVOY (ipilimumab) for the treatment of advanced renal cell carcinoma. …
Latest Video
New Stories
-
Companies already contemplating the risk of 'Pelosi plan'
October 18, 2019 - - Latest News -
Gilead: Elimination 'in reach' but more work required
October 18, 2019 - - Latest News -
Baby boom at Mundipharma in response to policy change
October 18, 2019 - - Latest News -
Bayer backs program targeting physical health in rural Australia
October 18, 2019 - - Latest News -
Patients welcome new action plan for osteoporosis
October 18, 2019 - - Latest News -
Pricing proposal will 'destroy' the industry and halve drug approvals
October 17, 2019 - - Latest News -
US proposal a 'game over' moment for Australian access
October 17, 2019 - - Comment